# The Role of Hypoketonemia in the Cancer Anorexia-Cachexia Syndrome

> **NIH NIH K08** · WEILL MEDICAL COLL OF CORNELL UNIV · 2020 · $149,682

## Abstract

Project Summary/Abstract
This proposal describes a five-year training program to launch a research career in a novel niche at the
intersection between endocrinology and cancer biology. The candidate is an endocrinology fellow at Weill Cornell
Medical Center, who has been training to become a physician-scientist for over ten years. The proposed
research will be carried out under the mentorship of Lewis C. Cantley, PhD, a leader in the field of cancer biology
and biochemistry who has trained numerous young investigators. An advisory committee of talented scientists
has also been assembled to offer guidance in career development and experimentation. The research
environment provides extensive resources, core facilities, and intellectual expertise. Therefore, it is an ideal
training setting in which to develop the requisite skills to become an independent physician-scientist. Participation
in didactic courses and professional development seminars will enhance the educational success of the program.
The cancer anorexia-cachexia syndrome (CACS) is a systemic metabolic disorder characterized by the
catabolism of nutrient-rich tissues, such as muscle and adipose tissue. Patients with CACS have reduced
mobility, worsened quality of life, and shortened survival. Therapeutic strategies to limit muscle loss are
predicted to reverse these deleterious outcomes, independent of direct cancer treatment. CACS has no effective
treatment or known etiology, in part, because animal models poorly mimic the findings in patients. However, in
preliminary experiments using an inducible, genetically engineered mouse model of non-small cell lung cancer
(NSCLC), the applicant has identified and characterized a model that reliably replicates CACS in humans. These
mice display a unique metabolic profile, characterized by the loss of PPARα-dependent ketone production by
the liver and a rise in endogenous glucocorticoid levels. Restoring ketone production using the PPARα agonist,
fenofibrate, reduces glucocorticoids and prevents the loss of skeletal muscle mass and body weight.
This proposal expands upon the preliminary experiments and seeks to clarify the causal relationship between
the observed changes in systemic metabolism and skeletal muscle loss in NSCLC-associated CACS. The
proposed aims are to test the hypothesis that skeletal muscle degradation results from the loss of ketone
production (Aim 1) or the subsequent rise in glucocorticoids (Aim 2). Additionally, this proposal will seek to
identify the tumor-released factor that initiates the reduction in hepatic PPARα expression in CACS mice (Aim
3). These experiments will elucidate the systemic metabolic signals driving muscle loss in an animal model of
NSCLC that accurately mimics the observed clinical syndrome. The expectations are to identify specific tumor-
secreted proteins that reduce hepatic ketone production, and demonstrate that ketone replacement therapy is a
useful therapeutic strategy. These results will not onl...

## Key facts

- **NIH application ID:** 9984322
- **Project number:** 5K08CA230318-03
- **Recipient organization:** WEILL MEDICAL COLL OF CORNELL UNIV
- **Principal Investigator:** Marcus DaSilva Goncalves
- **Activity code:** K08 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $149,682
- **Award type:** 5
- **Project period:** 2018-08-01 → 2023-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9984322

## Citation

> US National Institutes of Health, RePORTER application 9984322, The Role of Hypoketonemia in the Cancer Anorexia-Cachexia Syndrome (5K08CA230318-03). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/9984322. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*